Skip to main content
. Author manuscript; available in PMC: 2008 Jul 1.
Published in final edited form as: Anticancer Res. 2007;27(4A):1897–1900.

Figure 1.

Figure 1

Serum levels of osteopontin –OPN (A), S-100β (B), and MIA (C) in gender and age-matched controls, patients who remained disease free ( DF) for at least 10 years after treatment for primary uveal melanoma, and patients who developed metastatic uveal melanoma to the liver.

* Represents a statistically different level of marker as compared to the other groups.